ArticleExperimental and therapeutic medicine2019
Resveratrol downregulates the TLR4 signaling pathway to reduce brain damage in a rat model of focal cerebral ischemia.
Article in Experimental and therapeutic medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Effect and mechanisms of resveratrol in animal models of ischemic stroke: A systematic review and Bayesian meta-analysis.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023Pooled it
- A meta-analysis of resveratrol protects against cerebral ischemia/reperfusion injury: Evidence from rats studies and insight into molecular mechanisms.Frontiers in pharmacology · 2022Pooled it
- Neuroprotective effects of piracetam in vascular dementia: a review of toll-like receptor 4 -mediated neuroinflammatory pathways.Inflammopharmacology · 2026Review
- Natural products and neurocognitive disorders: Mechanistic insights and research advances (Review).Molecular medicine reports · 2026Review
- In vivo mechanisms of resveratrol liposomes in targeting the TLR4/NLRP3 pathway in lung cancer.Scientific reports · 2025Article
- A comprehensive review on the neuroprotective potential of resveratrol in ischemic stroke.Heliyon · 2024Review
- Therapeutic Effects of Intranasal Administration of Resveratrol on the Rat Model of Brain Ischemia.Heliyon · 2024Article
- Progress in the Treatment of Central Nervous System Diseases Based on Nanosized Traditional Chinese Medicine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Modulation of Abundance and Location of High-Mobility Group Box 1 in Human Microglia and Macrophages under Oxygen-Glucose Deprivation.ACS pharmacology & translational science · 2024Article
- Novel Multi-Antioxidant Approach for Ischemic Stroke Therapy Targeting the Role of Oxidative Stress.Biomedicines · 2024Review
- [Resveratrol protects dopaminergic neurons in a mouse model of Parkinson's disease by regulating the gut-brain axisNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Therapeutic Correlation of TLR-4 Mediated NF-κB Inflammatory Pathways in Ischemic Injuries.Current drug targets · 2024Review
- Targeting Neurological Disorders with Stilbenes: Bridging the Preclinical-Clinical Gap.International journal of biological sciences · 2024Review
- Sophoricoside attenuates neuronal injury and altered cognitive function by regulating the LTR-4/NF-κB/PI3K signalling pathway in anaesthetic-exposed neonatal rats.Archives of medical science : AMS · 2024Article
- Schisandrin B Protects against Ischemic Brain Damage by Regulating PI3K/AKT Signaling in Rats.Chinese journal of integrative medicine · 2023Article
- Potential Role of Natural Antioxidants in Countering Reperfusion Injury in Acute Myocardial Infarction and Ischemic Stroke.Antioxidants (Basel, Switzerland) · 2023Review
- Network pharmacology and molecular docking analysis on molecular targets and mechanisms ofExperimental and therapeutic medicine · 2022Article
- Antioxidant and neuroprotective actions of resveratrol in cerebrovascular diseases.Frontiers in pharmacology · 2022Review
- Oxidative Stress in the Brain: Basic Concepts and Treatment Strategies in Stroke.Antioxidants (Basel, Switzerland) · 2021Review
- Alpinia oxyphylla Miq extract reduces cerebral infarction by downregulating JNK-mediated TLR4/T3JAM- and ASK1-related inflammatory signaling in the acute phase of transient focal cerebral ischemia in rats.Chinese medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies have demonstrated that inflammation and disruption of the blood-brain barrier (BBB) are important pathological processes during focal cerebral ischemia. Therefore, the present study evaluated the neuroprotective effects of resveratrol against brain damage, inflammation and BBB disruption in rats with focal cerebral ischemia and assessed the potential underlying molecular mechanisms. Sprague-Dawley rats underwent cerebral ischemia/reperfusion (IR) and then received intraperitoneal resveratrol (10 and 100 mg/kg) 2 h following the onset of ischemia. Following 24 h of ischemia, neurological deficit scores, cerebral infarctions, morphological characteristics, cerebral water content, myeloperoxidase (MPO) activity and Evans blue extravasation were assessed. Additionally, the protein expression levels of Toll-like receptor 4 (TLR4) and nuclear factor (NF)-κB p65 were detected using western blot analyses, the mRNA expression levels of cyclooxygenase-2 (COX-2) and matrix metalloproteinase-9 (MMP-9) were examined by reverse-transcription polymerase chain reaction, and tumor necrosis factor (TNF)-α and interleukin (IL)-1β blood levels were determined by ELISA. Resveratrol significantly reduced neurological deficit scores, cerebral infarct sizes, neuronal injury, MPO activity and EB content. Cerebral ischemia increased the expression levels of TLR4, NF-κB p65, COX-2, MMP-9, TNF-α and IL-1β, but all of these factors were reduced by resveratrol. In conclusion, the present data suggest that resveratrol reduces inflammation, BBB disruption and brain damage in rats following focal cerebral ischemia. Additionally, the neuroprotective effects of resveratrol against cerebral ischemia may be associated with downregulation of the TLR4 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.